Request Demo
Study reveals T cells could provide more protection against Omicron in future vaccines
20 Feb 2024
VaccineImmunotherapyDrug ApprovalCell TherapymRNA
Researchers from Imperial College London (ICL) have revealed that T cells could provide more protection in COVID-19 vaccines against Omicron, a SARS-CoV-2 virus strain, than antibodies do.
The new review, pImperial College London (ICL)robe, offers new insights into the development of COVID-19 vaCOVID-19nd how T cells could play a crucial role in protecting people from these emerging variants.
Since being first identified in 2019, the SARS-CoV-2 virus has evolved with several variants andCOVID-19ants, such as Omicron, Pirola and Juno, leading to new waves of infection.
Although neutralising antibodies were considered to be the primary defence mechanism against COVID-19 during the pandemic, the virus has since evolved to become better infectiong them.
The new research reveals that memory T cells, which play a key role in the body’s adaptive imCOVID-19ponse to recurring viral infections, are more effective at recognising and combating the virus’ in comparison to antibodies.
This is especially true for people living with hybrid immunity obtained through vaccination and natural infection.viral infections
While further research is needed to understand the role of T cells in immunity to the virus’ different sinfectionesearchers suggest that boosting T cell responses could provide stronger and longer-lasting protection against different strains of the virus.
Danny Altmann, co-author of the review and professor of immunology, ICL, said: "This recent work reminds us that… we’re still very much locked in a fast-moving arms-race against the virus.
“We need to be alert to keep reappraising strategies, making it important to understand these different immune mechanisms, including T cells.”
Last month, Novavax announced that its updated COVID-19 vaccine, Nuvaxovid XBB.1.5, had been approved by the Medicines and Healthcare products Regulatory Agency for the active immunisation of individuals aged 12 years and older.
The protein-Novavaxaccine, which has been updatCOVID-19 vaccineCOVID-19clude the Nuvaxovid XBB.1.5om the SARS-CoV-2 omicron vMedicines and Healthcare products Regulatory Agencyesponses against the COVID-19 variants XBB.1.5, XBB.1.16 and XBB.2.3.
The vaccine also induced neutralising antibody responses to the newly emerging subvariants of the virus, JN.1, BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6, as well as strong CD4+ polyfCOVID-19l cellular (T-cell) responses against EG.5.1 and XBB.1.16.6.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.